Merck & Co Inc
Biden administration's Medicare drug price negotiations will face major tests in 2024
Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC. Anna Moneymaker | Getty Images U.S. patients and drugmakers will get a first glimpse of how much Medicare can negotiate down drug prices in 2024, setting the […]
Read More
Moderna, Merck vaccine with Keytruda delays return of deadly skin cancer after 3 years, data says
An exterior view of Moderna’s clinical manufacturing facility. David L. Ryan | Boston Globe | Getty Images Moderna and Merck‘s experimental cancer vaccine, when used in combination with Merck’s blockbuster therapy Keytruda, reduced the risk of death or relapse in patients with the most deadly form of skin cancer after three years, according to midstage […]
Read More
Pfizer shares fall as 2024 revenue and profit forecast disappoints
Shares of Pfizer fell Wednesday after the drugmaker forecast 2024 revenue and profit below Wall Street’s expectations, as it sees weak demand for its once-blockbuster Covid products. Pfizer also raised the target of its sweeping cost-cutting plan by $500 million, bringing the anticipated total to $4 billion. The company expects 2024 revenue of $58.5 billion […]
Read More
Investing in Space: Why Amazon bought rocket launches from rival SpaceX
United Launch Alliance Atlas V rocket carrying the first two demonstration satellites for Amazon’s Project Kuiper broadband internet constellation stands ready for launch on pad 41 at Cape Canaveral Space Force Station on October 5, 2023 in Cape Canaveral, Florida, United States. Paul Hennessey | Anadolu Agency | Getty Images CNBC’s Investing in Space newsletter […]
Read More
Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion
Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. Dado Ruvic | Reuters Biotech stocks rose Thursday as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10.1 billion. Shares of ImmunoGen jumped more than 80% on Thursday, putting it on track for its highest […]
Read More
Microsoft’s AI boost assisted cloud organization outpace rivals Amazon and Google in hottest quarter
In the superior-stakes cloud-computing struggle, Microsoft is outpacing its major rivals. Third-quarter final results are in for most mega-cap tech organizations just after a large week for tech earnings. On the cloud aspect, Microsoft claimed growth of 29% at Azure. That’s speedier than Google Cloud’s 22% expansion and additional than double the pace of expansion […]
Read More
Merck results beat expectations on strong Keytruda sales, surprise Covid drug growth
Merck headquarters in Rahway, New Jersey, on Tuesday, April 18, 2023. Christopher Occhicone | Bloomberg | Getty Images Merck on Thursday reported third-quarter revenue and adjusted earnings that topped expectations on strong sales of its blockbuster cancer drug Keytruda, HPV vaccine Gardasil and surprisingly, its Covid drug Lagevrio. The pharmaceutical giant also increased its full-year […]
Read More
Shares producing the greatest moves midday: SolarEdge, Regions Economic, Merck and extra
Check out out the companies creating headlines in midday trading. Schlumberger — The oilfield services stock dropped 2% after 3rd-quarter earnings missed Wall Road expectations. Schlumberger reported $8.31 billion in income for the quarter, underneath the consensus estimate of $8.33 billion from analysts polled by LSEG, previously known as Refinitiv. Also, Schlumberger claimed 78 cents […]
Read More
Drugmakers opt in to Medicare drug price negotiations – here’s what happens next
A pharmacist holds a bottle of the drug Eliquis, made by Pfizer Pharmaceuticals, at a pharmacy in Provo, Utah, January 9, 2020. George Frey | Reuters All drugmakers of the first 10 medicines selected for Medicare drug price negotiations have agreed to participate in the talks, even after many of them sued to halt the […]
Read More
Federal judge declines to block Medicare drug price negotiations
A pharmacist holds a bottle of the drug Eliquis, made by Pfizer Pharmaceuticals, at a pharmacy in Provo, Utah, January 9, 2020. George Frey | Reuters A federal judge on Friday declined to block the Biden administration from implementing Medicare drug price negotiations, upholding for now a controversial process that aims to make costly medications […]
Read More